WallStreetZenWallStreetZen

NASDAQ: ARDS
Aridis Pharmaceuticals Inc Stock

$0.65-0.04 (-5.8%)
Updated Feb 6, 2023
ARDS Price
$0.65
Fair Value Price
$0.80
Market Cap
$13.59M
52 Week Low
$0.57
52 Week High
$2.94
P/E
-0.36x
P/B
-0.38x
P/S
5.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.87M
Earnings
-$32.79M
Gross Margin
100%
Operating Margin
-1,126.77%
Profit Margin
-1,144.6%
Debt to Equity
-1.34
Operating Cash Flow
-$24M
Beta
0.46
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ARDS Overview

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARDS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARDS ($0.65) is undervalued by 17.87% relative to our estimate of its Fair Value price of $0.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ARDS ($0.65) is not significantly undervalued (17.87%) relative to our estimate of its Fair Value price of $0.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARDS due diligence checks available for Premium users.

Be the first to know about important ARDS news, forecast changes, insider trades & much more!

ARDS News

Valuation

ARDS fair value

Fair Value of ARDS stock based on Discounted Cash Flow (DCF)
Price
$0.65
Fair Value
$0.80
Undervalued by
18.24%
ARDS ($0.65) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARDS ($0.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARDS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.36x
Industry
11.5x
Market
14.99x

ARDS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.38x
Industry
5.06x

ARDS's financial health

Profit margin

Revenue
$399.0k
Net Income
-$8.2M
Profit Margin
-2,064.9%
ARDS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARDS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$12.1M
Liabilities
$47.9M
Debt to equity
-1.34
ARDS's short-term liabilities ($42.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARDS's short-term assets ($8.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARDS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARDS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.3M
Investing
$0.0
Financing
-$554.0k
ARDS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARDS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARDS$13.59M-5.22%-0.36x-0.38x
LIXT$13.50M+2.66%-1.76x2.11x
HILS$13.37M+4.50%-5.27x1.88x
ERNA$13.83M-1.26%-0.64x1.57x
GRAY$13.86M-1.68%-0.37x0.33x

Aridis Pharmaceuticals Stock FAQ

What is Aridis Pharmaceuticals's quote symbol?

NASDAQ: ARDS) Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol ARDS. Aridis Pharmaceuticals stock quotes can also be displayed as NASDAQ: ARDS.

If you're new to stock investing, here's how to buy Aridis Pharmaceuticals stock.

What is the 52 week high and low for Aridis Pharmaceuticals (NASDAQ: ARDS)?

(NASDAQ: ARDS) Aridis Pharmaceuticals's 52-week high was $2.94, and its 52-week low was $0.57. It is currently -77.79% from its 52-week high and 14.16% from its 52-week low.

How much is Aridis Pharmaceuticals stock worth today?

(NASDAQ: ARDS) Aridis Pharmaceuticals currently has 20,804,800 outstanding shares. With Aridis Pharmaceuticals stock trading at $0.65 per share, the total value of Aridis Pharmaceuticals stock (market capitalization) is $13.59M.

Aridis Pharmaceuticals stock was originally listed at a price of $13.00 in Aug 14, 2018. If you had invested in Aridis Pharmaceuticals stock at $13.00, your return over the last 4 years would have been -94.98%, for an annualized return of -52.66% (not including any dividends or dividend reinvestments).

How much is Aridis Pharmaceuticals's stock price per share?

(NASDAQ: ARDS) Aridis Pharmaceuticals stock price per share is $0.65 today (as of Feb 6, 2023).

What is Aridis Pharmaceuticals's Market Cap?

(NASDAQ: ARDS) Aridis Pharmaceuticals's market cap is $13.59M, as of Feb 8, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aridis Pharmaceuticals's market cap is calculated by multiplying ARDS's current stock price of $0.65 by ARDS's total outstanding shares of 20,804,800.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.